The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaksContinue reading
Author Archive: AZBio
New Online Resource Spotlights Life Science Investments in Arizona and Across the U.S.
We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $425 billion being invested to drive new R&D, expand manufacturing and create jobs nationwide. The continually updated database is accessible below through a state map of announcements that mention specific cities or states and also a tracker of every public commitment since January 2025.Continue reading
NuvOx and FYR Bio Announce NCI Funding for Liquid Biopsy Collaboration Supporting NuvOx’s Phase IIb Glioblastoma Trial
Tucson, AZ – September 26, 2025 – NuvOx Therapeutics, Inc. (“NuvOx”) and FYR Bio (“FYR”) today announced a collaboration pairing NuvOx’s Phase IIb glioblastoma trial of NanO₂ with FYR’s EV-based liquid-biopsy expertise to provide additional biomarker insights that support clinical development, through an NCI (a division of NIH) grant “Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic”.Continue reading
CND Life Sciences is Granted FDA Breakthrough Device Designation for Its Skin Biopsy-Based Syn-One Test®
SCOTTSDALE, AZ, October 7, 2025 – CND Life Sciences, Inc. (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for the company’s Syn-One Test® for aiding the diagnosis of synucleinopathies in patients aged 40 years and older with neurologic conditions that present with clinical features suggestive of a synucleinopathy.
The Journey of a Plasma Donation
Plasma Donors hold the missing puzzle piece for those who rely on plasma-derived therapies.
October is Plasma Awareness Month, an opportunity for CSL to raise awareness about the importance and need for plasma donations to manufacture life-saving therapies.Continue reading
Amgen Makes Repatha® Available Through AMGENNOW, A Direct-to-Patient Program in the U.S.
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price
THOUSAND OAKS, Calif. Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.Continue reading
FDA Announces New ANDA Prioritization Pilot to Support U.S. Generic Drug Manufacturing and Testing
[10/3/2025] Today, the U.S. Food and Drug Administration (FDA) is announcing a new pilot prioritization program for the review of abbreviated new drug applications (ANDAs) (ANDAs) that aims to spur and reward investment in U.S. drug manufacturing and research and development and strengthen the domestic pharmaceutical supply chain by providing faster reviews for generic companies who test and manufacture their products in the U.S.Continue reading
Falloposcope cancer screening tool testing advances to next steps
Jennifer Barton, PhD, is spearheading an effort to diagnose ovarian cancer earlier and give high-risk patients a new option.Continue reading
AdvaMed Releases Technical Performance and Safety Bulletin on “Remote Device Operations: Common Challenges and Mitigation Strategies”
WASHINGTON, D.C. – AdvaMed, the Medtech Association, recently published a technical performance and safety bulletin titled, “Remote Device Operations: Common Challenges and Mitigation Strategies” to help health care providers, device manufacturers, and IT teams navigate the complex landscape of remotely managing medical devices.Continue reading
U of A celebrates new AI-powered MRI and BIO5 Brain & Body Imaging Center
The new systems represent a leap in non-invasive imaging. The machines, powered by artificial intelligence, open new possibilities for treating neurological diseases such as Alzheimer’s and Parkinson’s, as well as expanding the capabilities for imaging the heart, lungs and liver – even for patients with metallic implants.